To view all full-text abstracts and accompayning presentations, if submitted, visit the Digestive Disease Week® (DDW) 2020 ePosters and ePapers site.
Abstract Tu1360: Risk of cancer with use of ranitidine: Results of a cohort study of 65 million US adults
Nabeeha Mohy–ud-din, MD, internal medicine resident, Allegheny Health Network, Pittsburgh, PA
Ranitidine is a histamine-2 (H2) receptor antagonist that is used for the prophylaxis and treatment of disorders associated with gastric acid secretion. Regulatory agencies throughout the world have asked for recall of ranitidine products given reports of contamination with Nitrosodimethylamine (NDMA), which is classified as a probable human carcinogen. The aim of this observational study was to analyze if ranitidine use leads to an increased risk of cancer using a large population-based database of 65 million patient records from over 40 health systems nationwide. Although this study did not find an increased incidence of cancer in patients taking ranitidine compared to those taking a comparable H2 blocker (famotidine), patients using ranitidine had a significantly higher incidence of cancer compared to the general population, owing at least in part to other risk factors that users of ranitidine had that are established risk factors for cancer, such as age, obesity, smoking, liver cirrhosis, alcohol use and a family history for cancer.